COPENHAGEN, FEBRUARY 15, 2017 – AntibioTx, a clinical stage, pharmaceutical company targeting microbiome-related disorders today announced that Lutz Wevelsiep, Ph.D. will be appointed as AntibioTx new VP of Drug Regulatory Affairs.

“Lutz will manage and oversee the Company’s international filings and relations with regulatory authorities” said Rasmus Toft-Kehler, CEO of AntibioTx ”Lutz brings more than 25 years’ of experience and has a proven track record from both multinational and start-up companies thus we feel confident that we have found the right person in charge of our overall regulatory strategies”. 

Dr. Wevelsiep has been Head of Global Regulatory Affairs for 16 years at Basilea Pharmaceutica. His track record includes successful completion of the European marketing authorization applications for Isavuconazole (Cresmba®), Ceftobiprole (Zevtera®) and Alitretinoin (Toctino®). Lutz holds a Ph.D. and Postdoc in chemistry from the Max-Planck Institute in Germany.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.